GlaxoSmithKline: FDA approves two-drug HIV regimen

(CercleFinance.com) - The US Food and Drug Administration has approved GlaxoSmithKline's two-drug regimen to treat adults with HIV-1, the infection that causes AIDS.


The FDA approved Dovato, a complete, once-daily, single-tablet regimen of dolutegravir and lamivudine for the treatment of HIV-1 infection in adults with no antiretroviral treatment history and with no known resistance to either compound.

The drug will offer patients a way to treat their HIV-1 infection with as few drugs as possible, marking a significant step in HIV treatment, GSK said.

Dovato is currently being reviewed by the European Medicines Agency (EMA) and regulatory authorities in Canada, Australia, Switzerland, and South Africa.

Copyright (c) 2019 CercleFinance.com. All rights reserved.